Clinical Trial Search

Primary: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.64; -1.59; -1.41 percentage of glycosylated hemoglobin — p=<0.001

Primary: Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N…

Primary: The Change in Serum Phosphorus — -0.23; -0.77; -0.97; -0.71 mg/dL

Primary: Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24) — 83.7; 84.5; 55.1 percentage of participants…

Primary: Overall Survival — 28.5; 25.3 months — p=0.2853

Primary: Wheelchair Skills Test (WST) — 90.4; 89.6 units on a scale — p=0.001

Primary: Measles Seropositivity at 24 and 36 Months — 98.92; 95.75; 94.37; 94.62 percentage of participants seropositive

Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540

Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 104; 121; 67 participants

Primary: Number of Participants With Clinical Adverse Events (AEs) — 1582; 804 Participants

Primary: Progression Free Survival (Part B) — 5.55; 2.89 Months — p=0.0030

Primary: Percentage of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) ≥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following a 4-dose Schedule…

Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min

Primary: Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics — 63.6; 55.8; 66.0 units on a scale — p=0.1675

Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 123; 130; 86 participants